ClinicalTrials.gg
CompletedNCT04995419Updated Oct 2, 2026Results posted

A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

A Phase 2 interventional study of Enfortumab vedotin in Metastatic Urothelial Cancer, sponsored by Astellas Pharma China, Inc.. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Updated Oct 2, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to determine the antitumor activity of enfortumab vedotin (EV) confirmed by the objective response rate (ORR).

This study also evaluated the effect of antibody-drug conjugate (ADC), total antibody (TAb) and monomethyl auristatin E (MMAE) in Chinese participants with locally advanced or metastatic urothelial cancer.

In addition, the study also evaluated the duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and immunogenicity determined by the incidence of antitherapeutic antibodies (ATA).

Safety and tolerability of EV in participants with locally advanced or metastatic urothelial cancer was also evaluated.

Read the detailed description

This study comprised of a single group of participants who received one dose of enfortumab vedotin (EV) on Days 1, 8 and 15 of every 4-week (28 days) cycle. Participants continued on study treatment until discontinuation.

After treatment discontinuation, participant had an end of treatment (EOT) visit for a 30-day Safety Follow-up.

Participants to discontinue to treatment for reasons other than disease progression were followed for response assessments.

A Pharmacokinetic (PK) cohort was available at some study centers. Participants enrolled at the PK cohort site(s) had intense PK samples collected after single and repeated doses.

02

Conditions studied

  • Metastatic Urothelial Cancer

Keywords

  • Enfortumab Vedotin
  • PADCEV
  • ASG-22CE
  • Pharmacokinetics
  • Urothelial cancer
03

In context

Lead sponsor

Astellas Pharma China, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has (ECOG) performance status of 0 or 1.
  • Participant must have or cytologically documented urothelial/transitional cell carcinoma of the bladder, renal pelvis, ureter or urethra. Other histologies including adenocarcinoma, squamous differentiation or mixed are eligible.
  • Participant has locally advanced or disease that is not amenable to curative intent treatment. Participants must have at baseline according to (RECIST) ( Version 1.1). Lesions in a prior radiation field must have progressed subsequent to radiotherapy to be considered measurable.
  • Participant must have received prior treatment with /PD-L1 inhibitor therapy in the locally advanced or metastatic urothelial cancer setting. Participants who received PD-1/PD-L1 therapy in the /adjuvant setting and had recurrent or progressive disease either during therapy or within 3 months of therapy completion are eligible.
  • Participant who received prior treatment with platinum-containing chemotherapy defined as those who received platinum in the neoadjuvant/adjuvant setting and had recurrent or progressive disease within 12 months of completion or received treatment with platinum in the locally advanced (defined as unresectable with curative intent) or metastatic setting.

    • Platinum based chemotherapy may include combination use with a PD-1 or PD-L1 inhibitor.
  • Participant has the following baseline laboratory data. If a participant has received a recent blood transfusion or growth factor, the hematology tests must be obtained ≥7 days after any growth factor and ≥ 28 days after any blood transfusion.

    • (ANC) ≥ 1.0 × 10\^9/L
    • count ≥ 100 × 10\^9/L
    • ≥ 9 g/dL
    • serum total (TBL) ≤ 1.5 × (ULN) or ≤ 3 × ULN for participants with Gilbert's disease
    • (CrCl) ≥ 30 mL/min as estimated per institutional standards or as measured by 24-hour urine collection ( [GFR] can also be used instead of CrCl).
    • (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN
  • Female participant is not pregnant and at least one of the following conditions apply:

    • Not a woman of (WOCBP)
    • WOCBP who agrees to follow the guidance from the time of through at least 6 months after the last dose of study treatment administration.
  • Female participant must agree not to breastfeed starting at screening and throughout the study period and for at least 6 months after the last dose of study treatment administration.
  • Female participant must not donate ova starting at first dose of study treatment and throughout the study period and for 6 months after the last dose of study treatment administration.
  • Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 6 months after the last dose of study treatment administration.
  • Male participant must not donate sperm during the treatment period and for 6 months after the last dose of study treatment administration.
  • Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 6 months after the last dose of study treatment administration.
  • Participant agrees not to participate in another interventional study while receiving study treatment in the present study.
  • Participant must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy.
  • Participant must have an anticipated of ≥ 3 months.

Exclusion criteria

Exclusion Criteria:

  • Participant has preexisting sensory or motor neuropathy Grade ≥ 2.
  • Participant has active central nervous system (CNS) . Participants with treated are permitted on study if all the following are true:

    • CNS metastases have been clinically stable for ≥ 6 weeks prior to screening.
    • If requiring treatment for CNS metastases, the participant is on a stable dose ≤ 20 mg/day of prednisone or equivalent for ≥ 2 weeks.
    • Baseline imaging scans show no evidence of new or enlarged brain metastasis.
    • Participant does not have .
  • Participant has ongoing toxicity (Grade 2 or higher with the exception of alopecia) associated with prior treatment (including systemic therapy, radiotherapy or surgery).
  • Participant with ongoing ≥ Grade 3 immunotherapy-related hypothyroidism or panhypopituitarism is excluded. Participant with ongoing immunotherapy-related colitis, uveitis, myocarditis or pneumonitis, or participants with other immunotherapy-related AEs requiring high doses of steroids (> 20 mg/day of prednisone or equivalent), is excluded. Participant with ≤ Grade 2 immunotherapy-related hypothyroidism or panhypopituitarism may be enrolled when well-maintained/controlled on a stable dose of hormone replacement therapy (if indicated).
  • Participant has a history of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes is defined as (HbA1c) ≥ 8 percent or HbA1c between 7 percent and \< 8 percent with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained.
  • Participant has prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE)-based antibody-drug conjugate (ADCs).
  • Participant has a second diagnosed within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Participants with non-melanoma skin cancer, localized prostate cancer treated with curative intent with no evidence of progression, low-risk or very low-risk (per standard guidelines) localized prostate cancer under active surveillance/watchful waiting without intent to treat, or carcinoma in situ of any type (if complete resection was performed) are allowed.
  • Participant is currently receiving systemic antimicrobial treatment for viral, bacterial or fungal infection at the time of first dose of study treatment. Routine antimicrobial prophylaxis is permitted.
  • Participants with a positive surface antigen and/or anti-hepatitis B core antibody and a negative polymerase chain reaction (PCR) assay at baseline should receive appropriate antiviral prophylaxis or regular surveillance monitoring as per local or institutional guidelines.
  • Active infection or known (HIV) infection. Participant who have been treated for hepatitis C infection are permitted if they have documented sustained virologic response of ≥ 12 weeks.
  • Participant has documented history of a cerebral vascular event (stroke or ), unstable angina, myocardial infarction or cardiac symptoms (including congestive heart failure) consistent with Class III-IV within 6 months prior to the first dose of study drug.
  • Participant had major surgery within 2 weeks or radiotherapy, chemotherapy, biologics, agents, and/or antitumor treatment with immunotherapy that is not completed 2 weeks prior to first dose of study drug. Toxicities from these therapies must have resolved or adequately stabilized before starting study treatment.
  • Participant has known to enfortumab vedotin or to any contained in the drug formulation of enfortumab vedotin (including histidine, trehalose dihydrate and polysorbate 20) or participant has known hypersensitivity to biopharmaceuticals produced in CHO cells.
  • Participant has known active keratitis or corneal ulcerations. Participant with superficial punctate keratitis is allowed if the disorder is being adequately treated.
  • Participant has any condition which makes the participant unsuitable for study participation.
  • Uncontrolled tumor-related bone pain or impending spinal cord compression. Participant requiring pain medication must be on a stable regimen for at least 2 weeks at the time of first dose.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Enfortumab Vedotin 1.25 mg/kg

    Participants received 1.25 milligrams per kilogram (mg/kg) of body weight enfortumab vedotin by intravenous (IV) infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first. Participants who had intense PK Sampling were enrolled in PK Cohort.

    Drug: Enfortumab vedotin

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors V1.1 (RECIST V1.1)

    ORR was defined as the percentage of participants with best overall response (BOR) as complete response (CR) or partial response (PR) based on the RECIST v1.1. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters.

    Time frame: From first dose up to progressive disease or death (maximum duration: 9.33 months)

  2. Pharmacokinetics (PK) of Antibody-Drug Conjugate (ADC), Total Antibody (TAb), in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 1

    Cmax was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 1: pre-dose, end of infusion (EOI), 2 hour, 4 hour post-dose (each cycle = 28 days)

  3. PK of Monomethyl Auristatin E (MMAE) in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 1

    Cmax was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 1: pre-dose, end of infusion (EOI), 2 hour, 4 hour post-dose (each cycle = 28 days)

  4. PK of ADC, TAb in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 15

    Cmax was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  5. PK of MMAE in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 15

    Cmax was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  6. PK of ADC , TAb in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 1

    As per planned analysis, if more than 50% of PK concentrations were below the limit of quantification (i.e 0) at a given time point, standard deviation was not reported.

    Time frame: Cycle 1 Day 1: pre-dose

  7. PK of MMAE in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 1

    As per planned analysis, if more than 50% of PK concentrations were below the limit of quantification (i.e 0) at a given time point, standard deviation was not reported.

    Time frame: Cycle 1 Day 1: pre-dose

  8. PK of ADC, TAb in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 15

    Ctrough was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose

  9. PK of MMAE in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 15

    Ctrough was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose

  10. PK of ADC, TAb, MMAE in Serum: Time to Maximum Concentration (Tmax) at Cycle 1 Day 1

    Tmax was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 1: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  11. PK of ADC, TAb, MMAE in Serum: Time to Maximum Concentration (Tmax) at Cycle 1 Day 15

    Tmax was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  12. PK of ADC, TAb, MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 28 (AUC0-28d) at Cycle 1 Day 1

    AUC0-28d was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 1: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  13. PK of ADC, TAb, MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 28 (AUC0-28d) at Cycle 1 Day 15

    AUC0-28d was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  14. PK of ADC, TAb in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 1

    AUC0-7d was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 1 : pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  15. PK of MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 1

    AUC0-7d was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 1 : pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  16. PK of ADC, TAb in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 15

    AUC0-7d was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  17. PK of MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 15

    AUC0-7d was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  18. PK of ADC, TAb, MMAE in Plasma: Accumulation Ratio of Cmax (RacCmax)

    Accumulation ratio is the ratio of Cmax after the dosing interval (Cycle 1 Day 15) divided by Cmax after the first dosing interval (Cycle 1 Day 1).

    Time frame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  19. PK of ADC, TAb, MMAE in Serum: Accumulation Ratio of AUC0-7d ( RacAUC0-7d)

    RacAUC0-7d was calculated using AUC0-7d and derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  20. PK of ADC, TAb, MMAE in Serum: Terminal Elimination Half-life (t1/2)

    t1/2 was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  21. PK of ADC, TAb, MMAE in Serum: Systemic Clearance (CL)

    CL was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

  22. PK of ADC, TAb, MMAE in Serum: Volume of Distribution at Steady State (Vss)

    Vss was derived from the PK blood samples collected.

    Time frame: Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

Secondary outcomes

  1. Objective Response Rate (ORR) as Per Investigator Assessment

    ORR was defined as the percentage of participants with BOR as CR or PR based on the RECIST v1.1 as per investigator's assesment. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters.

    Time frame: From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)

  2. Duration of Response (DOR) as Per RECIST V1.1 Per IRC

    DOR: time from the date of the first CR/PR (whichever is first recorded) that was subsequently confirmed as assessed by IRC to the date of documented progressive disease. or death due to any cause whichever occurred first. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. Progressive Disease:\>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression.

    Time frame: From date of the first CR/PR up to progressive disease or death (maximum duration: 48.69 months)

  3. Duration of Response (DOR) as Per RECIST V1.1 Per Investigator's Assessment

    DOR: time from the date of the first CR/PR (whichever is first recorded) that was subsequently confirmed as assessed by Investigator's Assesment to the date of documented progressive disease or death due to any cause whichever occurred first. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. Progressive disease:\>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression.

    Time frame: From date of the first CR/PR up to progressive disease or death (maximum duration: 48.69 months)

  4. Disease Control Rate (DCR) as Per RECIST V1.1 Per IRC

    DCR: percentage of participants with a CR, PR or SD based on RECIST v1.1 as assessed by IRC. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. SD was defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference the smallest sum of diameters while on study drug. Progressive disease:\>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression.

    Time frame: From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)

  5. Disease Control Rate (DCR) as Per RECIST V1.1 Per Investigator's Assesment

    DCR: percentage of participants with a CR, PR or SD based on RECIST v1.1 as assessed by investigator's assessment. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. SD was defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference the smallest sum of diameters while on study drug. Progressive disease:\>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression.

    Time frame: From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)

  6. Progression Free-Survival Per RECIST V1.1 Per IRC

    PFS: time from first dose of the study drug until date of documented radiological disease progression per IRC based on RECIST V1.1, or until death due to any cause, whichever occurred first. Progressive disease: \>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression. A participant who neither progressed nor died was censored at date of last radiological assessment (RA)/ date of randomization if no post-baseline RA was available. Participants who received any further anticancer therapy (ACT) for disease before radiological progression was censored at date of last RA before ACT started and participants who had PD/death after \>=2 missed RAs were censored at last RA prior to 2 or more missed RAs. Kaplan-Meier estimates was used.

    Time frame: From first dose up to progressive disease or death (maximum duration: 48.69 months)

  7. Progression Free-Survival Per RECIST V1.1 Per Investigator's Assessment

    PFS: time from first dose of the study drug until date of documented radiological disease progression per investigator based on RECIST V1.1, or until death due to any cause, whichever occurred first. Progressive disease: \>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression. A participant who neither progressed nor died was censored at date of last RA/ date of randomization if no post-baseline RA was available. Participants who received any further ACT for disease before radiological progression was censored at date of last RA before ACT started and participants who had progressive disease/death after \>=2 missed RAs were censored at last RA prior to 2 or more missed RAs. Kaplan-Meier estimates was used.

    Time frame: From first dose up to progressive disease or death (maximum duration: 48.69 months)

  8. Overall Survival (OS)

    OS was defined as the time from first dose of the study drug until the documented date of death from any cause. OS was analyzed using Kaplan-Meier estimates. Participants who were still alive at the time of data cutoff date were to be censored at the last known alive date or at the data cutoff date, whichever was earlier.

    Time frame: From first dose up to death (maximum duration: 48.69 months)

  9. Number of Participants With Antitherapeutic Antibodies (ATA)

    Number of participants with ATA were reported.

    Time frame: From first dose until 9.33 months

  10. Number of Participants With Treatment Emergent Adverse Events

    An AE is any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE is defined as an adverse event observed after starting administration of the study drug and within 30 days after taking the last dose of study drug. Any post-baseline abnormal laboratory tests, vital sign measurements, or 12-lead electrocardiogram (ECG) measurements were reported as TEAEs.

    Time frame: Up to 47 months

  11. Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)

    ECOG performance status was measured on an 6 point scale. 0-Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead. Number of participants with ECOG PS was reported.

    Time frame: End of Treatment 30 day Follow-up (47 months)

07

Results

Posted Sep 13, 2023

Participant flow

Adult Chinese participants with locally advanced or metastatic urothelial cancer (mUC) who had received a platinum-containing chemotherapy and programmed cell death protein-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors.

Participant flow — Overall Study
MilestoneEnfortumab Vedotin 1.25 mg/kg
Started40
Completed0
Not completed40
Withdrew: Death31
Withdrew: Long term follow-up terminated by sponsor9

Outcome measures

SecondaryObjective Response Rate (ORR) as Per Investigator Assessment

ORR was defined as the percentage of participants with BOR as CR or PR based on the RECIST v1.1 as per investigator's assesment. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters.

Time frame:
From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) as Per Investigator Assessment
percentage of participantsEnfortumab Vedotin 1.25 mg/kg
Objective Response Rate (ORR) as Per Investigator Assessment42.5 (27.0 to 59.1)
SecondaryDuration of Response (DOR) as Per RECIST V1.1 Per IRC

DOR: time from the date of the first CR/PR (whichever is first recorded) that was subsequently confirmed as assessed by IRC to the date of documented progressive disease. or death due to any cause whichever occurred first. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. Progressive Disease:\>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression.

Time frame:
From date of the first CR/PR up to progressive disease or death (maximum duration: 48.69 months)
Reported as:
Median · months
Duration of Response (DOR) as Per RECIST V1.1 Per IRC
monthsEnfortumab Vedotin 1.25 mg/kg
Duration of Response (DOR) as Per RECIST V1.1 Per IRC18.46 (3.91 to NA)
SecondaryDuration of Response (DOR) as Per RECIST V1.1 Per Investigator's Assessment

DOR: time from the date of the first CR/PR (whichever is first recorded) that was subsequently confirmed as assessed by Investigator's Assesment to the date of documented progressive disease or death due to any cause whichever occurred first. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. Progressive disease:\>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression.

Time frame:
From date of the first CR/PR up to progressive disease or death (maximum duration: 48.69 months)
Reported as:
Median · months
Duration of Response (DOR) as Per RECIST V1.1 Per Investigator's Assessment
monthsEnfortumab Vedotin 1.25 mg/kg
Duration of Response (DOR) as Per RECIST V1.1 Per Investigator's Assessment12.58 (3.52 to 30.36)
SecondaryDisease Control Rate (DCR) as Per RECIST V1.1 Per IRC

DCR: percentage of participants with a CR, PR or SD based on RECIST v1.1 as assessed by IRC. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. SD was defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference the smallest sum of diameters while on study drug. Progressive disease:\>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression.

Time frame:
From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) as Per RECIST V1.1 Per IRC
percentage of participantsEnfortumab Vedotin 1.25 mg/kg
Disease Control Rate (DCR) as Per RECIST V1.1 Per IRC72.5 (56.1 to 85.4)
SecondaryDisease Control Rate (DCR) as Per RECIST V1.1 Per Investigator's Assesment

DCR: percentage of participants with a CR, PR or SD based on RECIST v1.1 as assessed by investigator's assessment. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. SD was defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference the smallest sum of diameters while on study drug. Progressive disease:\>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression.

Time frame:
From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR) as Per RECIST V1.1 Per Investigator's Assesment
percentage of participantsEnfortumab Vedotin 1.25 mg/kg
Disease Control Rate (DCR) as Per RECIST V1.1 Per Investigator's Assesment82.5 (67.2 to 92.7)
SecondaryProgression Free-Survival Per RECIST V1.1 Per IRC

PFS: time from first dose of the study drug until date of documented radiological disease progression per IRC based on RECIST V1.1, or until death due to any cause, whichever occurred first. Progressive disease: \>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression. A participant who neither progressed nor died was censored at date of last radiological assessment (RA)/ date of randomization if no post-baseline RA was available. Participants who received any further anticancer therapy (ACT) for disease before radiological progression was censored at date of last RA before ACT started and participants who had PD/death after \>=2 missed RAs were censored at last RA prior to 2 or more missed RAs. Kaplan-Meier estimates was used.

Time frame:
From first dose up to progressive disease or death (maximum duration: 48.69 months)
Reported as:
Median · months
Progression Free-Survival Per RECIST V1.1 Per IRC
monthsEnfortumab Vedotin 1.25 mg/kg
Progression Free-Survival Per RECIST V1.1 Per IRC4.90 (3.65 to 8.90)
SecondaryProgression Free-Survival Per RECIST V1.1 Per Investigator's Assessment

PFS: time from first dose of the study drug until date of documented radiological disease progression per investigator based on RECIST V1.1, or until death due to any cause, whichever occurred first. Progressive disease: \>= 20% increase in sum of diameters of target lesions taking as reference the smallest sum, and sum must also demonstrate an absolute increase of \>= 5 mm. Appearance of 1 or more new lesions is also considered progression. A participant who neither progressed nor died was censored at date of last RA/ date of randomization if no post-baseline RA was available. Participants who received any further ACT for disease before radiological progression was censored at date of last RA before ACT started and participants who had progressive disease/death after \>=2 missed RAs were censored at last RA prior to 2 or more missed RAs. Kaplan-Meier estimates was used.

Time frame:
From first dose up to progressive disease or death (maximum duration: 48.69 months)
Reported as:
Median · months
Progression Free-Survival Per RECIST V1.1 Per Investigator's Assessment
monthsEnfortumab Vedotin 1.25 mg/kg
Progression Free-Survival Per RECIST V1.1 Per Investigator's Assessment4.90 (3.75 to 7.59)
SecondaryOverall Survival (OS)

OS was defined as the time from first dose of the study drug until the documented date of death from any cause. OS was analyzed using Kaplan-Meier estimates. Participants who were still alive at the time of data cutoff date were to be censored at the last known alive date or at the data cutoff date, whichever was earlier.

Time frame:
From first dose up to death (maximum duration: 48.69 months)
Reported as:
Median · months
Overall Survival (OS)
monthsEnfortumab Vedotin 1.25 mg/kg
Overall Survival (OS)11.93 (8.71 to 14.62)
SecondaryNumber of Participants With Antitherapeutic Antibodies (ATA)

Number of participants with ATA were reported.

Time frame:
From first dose until 9.33 months
Reported as:
Count of participants · Participants
Number of Participants With Antitherapeutic Antibodies (ATA)
ParticipantsEnfortumab Vedotin 1.25 mg/kg
Baseline Negative, Negative post-baseline37
Baseline Negative, Positive post-baseline0
Baseline Positive, Negative post-baseline1
Baseline Positive, Positive post-baseline0
SecondaryNumber of Participants With Treatment Emergent Adverse Events

An AE is any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAE is defined as an adverse event observed after starting administration of the study drug and within 30 days after taking the last dose of study drug. Any post-baseline abnormal laboratory tests, vital sign measurements, or 12-lead electrocardiogram (ECG) measurements were reported as TEAEs.

Time frame:
Up to 47 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsEnfortumab Vedotin 1.25 mg/kg
Number of Participants With Treatment Emergent Adverse Events40
SecondaryNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)

ECOG performance status was measured on an 6 point scale. 0-Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead. Number of participants with ECOG PS was reported.

Time frame:
End of Treatment 30 day Follow-up (47 months)
Reported as:
Count of participants · Participants
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
ParticipantsEnfortumab Vedotin 1.25 mg/kg
ECOG PS= 03
ECOG PS= 120
ECOG PS= 21
ECOG PS= 31
ECOG PS= 40
ECOG PS= 50
PrimaryObjective Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors V1.1 (RECIST V1.1)

ORR was defined as the percentage of participants with best overall response (BOR) as complete response (CR) or partial response (PR) based on the RECIST v1.1. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters.

Time frame:
From first dose up to progressive disease or death (maximum duration: 9.33 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors V1.1 (RECIST V1.1)
percentage of participantsEnfortumab Vedotin 1.25 mg/kg
Objective Response Rate (ORR) as Per Response Evaluation Criteria in Solid Tumors V1.1 (RECIST V1.1)37.5 (22.7 to 54.2)
PrimaryPharmacokinetics (PK) of Antibody-Drug Conjugate (ADC), Total Antibody (TAb), in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 1

Cmax was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 1: pre-dose, end of infusion (EOI), 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · micrograms per milliliter (ug/mL)
Pharmacokinetics (PK) of Antibody-Drug Conjugate (ADC), Total Antibody (TAb), in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 1
micrograms per milliliter (ug/mL)Enfortumab Vedotin 1.25 mg/kg
ADC28.1 ± 4.52
TAb31.7 ± 5.73
PrimaryPK of Monomethyl Auristatin E (MMAE) in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 1

Cmax was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 1: pre-dose, end of infusion (EOI), 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · nanograms per milliliter (ng/mL)
PK of Monomethyl Auristatin E (MMAE) in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 1
nanograms per milliliter (ng/mL)Enfortumab Vedotin 1.25 mg/kg
PK of Monomethyl Auristatin E (MMAE) in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 13.33 ± 1.74
PrimaryPK of ADC, TAb in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 15

Cmax was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · ug/mL
PK of ADC, TAb in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 15
ug/mLEnfortumab Vedotin 1.25 mg/kg
ADC27.6 ± 4.01
TAb34.4 ± 4.64
PrimaryPK of MMAE in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 15

Cmax was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · ng/mL
PK of MMAE in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 15
ng/mLEnfortumab Vedotin 1.25 mg/kg
PK of MMAE in Serum: Maximum Concentration (Cmax) at Cycle 1 Day 154.49 ± 3.58
PrimaryPK of ADC , TAb in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 1

As per planned analysis, if more than 50% of PK concentrations were below the limit of quantification (i.e 0) at a given time point, standard deviation was not reported.

Time frame:
Cycle 1 Day 1: pre-dose
Reported as:
Mean · ug/mL
PK of ADC , TAb in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 1
ug/mLEnfortumab Vedotin 1.25 mg/kg
ADC0 ± NA
TAb0 ± NA
PrimaryPK of MMAE in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 1

As per planned analysis, if more than 50% of PK concentrations were below the limit of quantification (i.e 0) at a given time point, standard deviation was not reported.

Time frame:
Cycle 1 Day 1: pre-dose
Reported as:
Mean · ng/mL
PK of MMAE in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 1
ng/mLEnfortumab Vedotin 1.25 mg/kg
PK of MMAE in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 10 ± NA
PrimaryPK of ADC, TAb in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 15

Ctrough was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose
Reported as:
Mean · ug/mL
PK of ADC, TAb in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 15
ug/mLEnfortumab Vedotin 1.25 mg/kg
ADC1020 ± 410
TAb4620 ± 1590
PrimaryPK of MMAE in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 15

Ctrough was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose
Reported as:
Mean · picograms per milliliter (pg/mL)
PK of MMAE in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 15
picograms per milliliter (pg/mL)Enfortumab Vedotin 1.25 mg/kg
PK of MMAE in Serum: Trough Concentration (Ctrough) at Cycle 1 Day 151880 ± 1680
PrimaryPK of ADC, TAb, MMAE in Serum: Time to Maximum Concentration (Tmax) at Cycle 1 Day 1

Tmax was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 1: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Median · days
PK of ADC, TAb, MMAE in Serum: Time to Maximum Concentration (Tmax) at Cycle 1 Day 1
daysEnfortumab Vedotin 1.25 mg/kg
ADC0.0340 (0.0278 to 0.0917)
TAb0.0340 (0.0243 to 1.89)
MMAE2.00 (1.87 to 2.93)
PrimaryPK of ADC, TAb, MMAE in Serum: Time to Maximum Concentration (Tmax) at Cycle 1 Day 15

Tmax was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Median · days
PK of ADC, TAb, MMAE in Serum: Time to Maximum Concentration (Tmax) at Cycle 1 Day 15
daysEnfortumab Vedotin 1.25 mg/kg
ADC0.0337 (0.0257 to 0.0805)
TAb0.0337 (0.0278 to 0.0854)
MMAE1.93 (0.858 to 2.92)
PrimaryPK of ADC, TAb, MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 28 (AUC0-28d) at Cycle 1 Day 1

AUC0-28d was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 1: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

No measurements were reported for this outcome.

PrimaryPK of ADC, TAb, MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 28 (AUC0-28d) at Cycle 1 Day 15

AUC0-28d was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)

No measurements were reported for this outcome.

PrimaryPK of ADC, TAb in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 1

AUC0-7d was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 1 : pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · day*ug/mL
PK of ADC, TAb in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 1
day*ug/mLEnfortumab Vedotin 1.25 mg/kg
ADC32.4 ± 6.24
TAb77.4 ± 17.3
PrimaryPK of MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 1

AUC0-7d was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 1 : pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · day*ng/mL
PK of MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 1
day*ng/mLEnfortumab Vedotin 1.25 mg/kg
PK of MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 116.9 ± 9.21
PrimaryPK of ADC, TAb in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 15

AUC0-7d was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · day*ug/mL
PK of ADC, TAb in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 15
day*ug/mLEnfortumab Vedotin 1.25 mg/kg
ADC36.5 ± 7.93
TAb94.7 ± 15.7
PrimaryPK of MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 15

AUC0-7d was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · day*ng/mL
PK of MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 15
day*ng/mLEnfortumab Vedotin 1.25 mg/kg
PK of MMAE in Serum: Area Under Concentration-time Curve From 0 to Day 7 (AUC0-7d) at Cycle 1 Day 1523.3 ± 16.4
PrimaryPK of ADC, TAb, MMAE in Plasma: Accumulation Ratio of Cmax (RacCmax)

Accumulation ratio is the ratio of Cmax after the dosing interval (Cycle 1 Day 15) divided by Cmax after the first dosing interval (Cycle 1 Day 1).

Time frame:
Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · ratio
PK of ADC, TAb, MMAE in Plasma: Accumulation Ratio of Cmax (RacCmax)
ratioEnfortumab Vedotin 1.25 mg/kg
ADC1.03 ± 0.150
TAb1.13 ± 0.137
MMAE1.28 ± 0.499
PrimaryPK of ADC, TAb, MMAE in Serum: Accumulation Ratio of AUC0-7d ( RacAUC0-7d)

RacAUC0-7d was calculated using AUC0-7d and derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · ratio
PK of ADC, TAb, MMAE in Serum: Accumulation Ratio of AUC0-7d ( RacAUC0-7d)
ratioEnfortumab Vedotin 1.25 mg/kg
ADC1.20 ± 0.228
TAb1.29 ± 0.208
MMAE1.32 ± 0.486
PrimaryPK of ADC, TAb, MMAE in Serum: Terminal Elimination Half-life (t1/2)

t1/2 was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Median · days
PK of ADC, TAb, MMAE in Serum: Terminal Elimination Half-life (t1/2)
daysEnfortumab Vedotin 1.25 mg/kg
ADC2.81 (2.28 to 3.70)
TAb3.82 (3.11 to 5.49)
MMAE3.12 (2.83 to 3.82)
PrimaryPK of ADC, TAb, MMAE in Serum: Systemic Clearance (CL)

CL was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · Liters/hour (L/hr)
PK of ADC, TAb, MMAE in Serum: Systemic Clearance (CL)
Liters/hour (L/hr)Enfortumab Vedotin 1.25 mg/kg
ADC0.104 ± 0.0239
TAb0.0396 ± 0.00847
MMAE196 ± 76.2
PrimaryPK of ADC, TAb, MMAE in Serum: Volume of Distribution at Steady State (Vss)

Vss was derived from the PK blood samples collected.

Time frame:
Cycle 1 Day 15: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)
Reported as:
Mean · Liters
PK of ADC, TAb, MMAE in Serum: Volume of Distribution at Steady State (Vss)
LitersEnfortumab Vedotin 1.25 mg/kg
ADC7.13 ± 1.39
TAb4.97 ± 1.27
MMAE28900 ± 10800

Adverse events

Collected over All-cause mortality: up to 48.69 months; AEs: up to 47 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enfortumab Vedotin 1.25 mg/kg31/40 (77.5%)20/40 (50%)40/40 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventEnfortumab Vedotin 1.25 mg/kg
PneumoniaInfections and infestations5/40
RashSkin and subcutaneous tissue disorders3/40
LeukopeniaBlood and lymphatic system disorders2/40
Neutrophil count decreasedInvestigations2/40
Diabetes mellitusMetabolism and nutrition disorders2/40
HypokalaemiaMetabolism and nutrition disorders2/40
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/40
Drug eruptionSkin and subcutaneous tissue disorders2/40
PancytopeniaBlood and lymphatic system disorders1/40
Acute coronary syndromeCardiac disorders1/40
Most frequent other events
Showing 10 of 105
Most frequent other events
EventEnfortumab Vedotin 1.25 mg/kg
AnaemiaBlood and lymphatic system disorders29/40
Aspartate aminotransferase increasedInvestigations28/40
Decreased appetiteMetabolism and nutrition disorders27/40
DiarrhoeaGastrointestinal disorders21/40
NauseaGastrointestinal disorders20/40
HyperglycaemiaMetabolism and nutrition disorders20/40
ConstipationGastrointestinal disorders19/40
Alanine aminotransferase increasedInvestigations19/40
Neutrophil count decreasedInvestigations19/40
HypokalaemiaMetabolism and nutrition disorders19/40

Baseline characteristics

Full analysis set (FAS) included all participants who were enrolled and received any amount of study drug in the study.

Age, Continuous
Age, Continuous(years)Enfortumab Vedotin 1.25 mg/kg
Mean60.3 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Enfortumab Vedotin 1.25 mg/kg
Female9
Male31
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enfortumab Vedotin 1.25 mg/kg
Hispanic or Latino0
Not Hispanic or Latino40
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enfortumab Vedotin 1.25 mg/kg
American Indian or Alaska Native0
Asian40
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

7 sites
  • Site CN86001
    Beijing, China
  • Site CN86009
    Changsha, China
  • Site CN86002
    Guangzhou, China
  • Site CN86006
    Hangzhou, China
  • Site CN86007
    Nanjing, China
  • Site CN86004
    Shanghai, China
  • Site CN86003
    Wuhan, China
09

References and documents

Publications

  • Li S, Shi Y, Dong H, Guo H, Xie Y, Sun Z, Zhang X, Kim E, Zhang J, Li Y, Xu C, Kadeerbai H, Lee S, Gorla S, Guo J, Sheng X. Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China. Cancer Med. 2024 Nov;13(21):e70368. doi: 10.1002/cam4.70368. PubMed 39530574 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in May 2022, 9 months.

Results were first posted in Sep 2023, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 9, 2021
StartActual
Jul 22, 2021
Primary completionActual
May 13, 2022
CompletionActual
Aug 27, 2025
Results first posted
Sep 13, 2023
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 2, 2026
Secondary outcomes
10 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameDuration of Response (DOR) as Per RECIST V1.1 Per IRCFrom date of the first CR/PR up to progressive disease or death (maximum duration: 9.33 months) → From date of the first CR/PR up to progressive disease or death (maximum duration: 48.69 months)
  • Time frameDuration of Response (DOR) as Per RECIST V1.1 Per Investigator's AssessmentFrom date of the first CR/PR up to progressive disease or death (maximum duration: 9.33 months) → From date of the first CR/PR up to progressive disease or death (maximum duration: 48.69 months)
  • Time frameObjective Response Rate (ORR) as Per Investigator AssessmentFrom first dose up to progressive disease or death (maximum duration: 9.33 months) → From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)
  • Time frameDisease Control Rate (DCR) as Per RECIST V1.1 Per IRCFrom first dose up to progressive disease or death (maximum duration: 9.33 months) → From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)
  • Time frameDisease Control Rate (DCR) as Per RECIST V1.1 Per Investigator's AssesmentFrom first dose up to progressive disease or death (maximum duration: 9.33 months) → From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)
  • Time frameProgression Free-Survival Per RECIST V1.1 Per IRCFrom first dose up to progressive disease or death (maximum duration: 9.33 months) → From first dose up to progressive disease or death (maximum duration: 48.69 months)
  • Time frameProgression Free-Survival Per RECIST V1.1 Per Investigator's AssessmentFrom first dose up to progressive disease or death (maximum duration: 9.33 months) → From first dose up to progressive disease or death (maximum duration: 48.69 months)
  • Time frameOverall Survival (OS)From first dose up to death (maximum duration: 9.33 months) → From first dose up to death (maximum duration: 48.69 months)
  • Time frameNumber of Participants With Treatment Emergent Adverse EventsBaseline up to 9.33 months → Up to 47 months
  • Time frameNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)End of Treatment (Baseline up to 9.33 months) → End of Treatment 30 day Follow-up (47 months)
  • DescriptionNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): how it is measured was reworded
  • DescriptionNumber of Participants With Treatment Emergent Adverse Events: how it is measured was reworded
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Posted results revised
    Secondary outcomes 10 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameDuration of Response (DOR) as Per RECIST V1.1 Per IRCFrom date of the first CR/PR up to progressive disease or death (maximum duration: 9.33 months) → From date of the first CR/PR up to progressive disease or death (maximum duration: 48.69 months)
    • Time frameDuration of Response (DOR) as Per RECIST V1.1 Per Investigator's AssessmentFrom date of the first CR/PR up to progressive disease or death (maximum duration: 9.33 months) → From date of the first CR/PR up to progressive disease or death (maximum duration: 48.69 months)
    • Time frameObjective Response Rate (ORR) as Per Investigator AssessmentFrom first dose up to progressive disease or death (maximum duration: 9.33 months) → From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)
    • Time frameDisease Control Rate (DCR) as Per RECIST V1.1 Per IRCFrom first dose up to progressive disease or death (maximum duration: 9.33 months) → From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)
    • Time frameDisease Control Rate (DCR) as Per RECIST V1.1 Per Investigator's AssesmentFrom first dose up to progressive disease or death (maximum duration: 9.33 months) → From first dose up to progressive disease or death at the time of primary analysis cut-off (maximum duration: 9.33 months)
    • Time frameProgression Free-Survival Per RECIST V1.1 Per IRCFrom first dose up to progressive disease or death (maximum duration: 9.33 months) → From first dose up to progressive disease or death (maximum duration: 48.69 months)
    • Time frameProgression Free-Survival Per RECIST V1.1 Per Investigator's AssessmentFrom first dose up to progressive disease or death (maximum duration: 9.33 months) → From first dose up to progressive disease or death (maximum duration: 48.69 months)
    • Time frameOverall Survival (OS)From first dose up to death (maximum duration: 9.33 months) → From first dose up to death (maximum duration: 48.69 months)
    • Time frameNumber of Participants With Treatment Emergent Adverse EventsBaseline up to 9.33 months → Up to 47 months
    • Time frameNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)End of Treatment (Baseline up to 9.33 months) → End of Treatment 30 day Follow-up (47 months)
    • DescriptionNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): how it is measured was reworded
    • DescriptionNumber of Participants With Treatment Emergent Adverse Events: how it is measured was reworded
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04995419
Collaborators
Seagen Inc.
Responsible party
Sponsor
First posted
Aug 9, 2021
Start date
Jul 22, 2021
Primary completion
May 13, 2022
Completion
Aug 27, 2025
Results posted
Sep 13, 2023
Last update
Oct 2, 2026

Study contacts

Senior Medical Science Manager
study director · Astellas Pharma China, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enfortumab vedotin

Start the discussion